Cancer
DREAM3R
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Trial overview
Topic
Mesothelioma
Description
Durvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial.
Eligibility criteria
- Untreated stage IV Mesothelioma, please enquire for more details.
Study details
The treatment is comparing standard of care chemotherapy to chemotherapy with Atezolizumab, the study is randomised with a ratio of 2:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
Further information
For more information regarding this clinical trial click here.
Location